Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (NRIX) is a clinical-stage biopharmaceutical leader developing targeted protein degradation therapies for cancer and immune disorders. This page provides centralized access to official news and press releases, offering critical insights into the company’scientific advancements and strategic direction.
Investors and researchers will find updates on clinical trial progress, regulatory milestones, and strategic collaborations with industry partners. The resource covers Nurix’s innovative pipeline, including BTK degraders for oncology and CBL-B inhibitors for immune modulation, alongside financial developments and operational updates.
Content is organized to highlight therapeutic innovations, scientific publications, and partnership announcements, ensuring stakeholders stay informed about Nurix’s progress in advancing oral small molecule therapies. Bookmark this page for real-time updates on Nurix’s pioneering work in E3 ligase modulation and protein homeostasis.
Nurix Therapeutics (Nasdaq: NRIX) presented Phase 1 data for BTK degrader bexobrutideg (NX-5948) in relapsed/refractory Waldenström macroglobulinemia at ASH on December 8, 2025.
In 31 treated patients (median age 71), 28 were evaluable and achieved an objective response rate (ORR) of 75.0% (VGPR 10.7%, PR 50.0%, MR 14.3%). Median follow-up was 8.1 months; median duration of response and median progression-free survival were not reached. Responses occurred regardless of MYD88/CXCR4 status, and 14 patients remained on treatment >6 months.
Safety was manageable: common AEs included neutropenia 29.0% and diarrhea 25.8%; no dose-limiting toxicities or grade 5 AEs were observed.
Nurix (NASDAQ: NRIX) reported updated Phase 1a/1b data for bexobrutideg (NX-5948) in relapsed/refractory CLL/SLL presented at ASH 2025.
Key clinical metrics: ORR 83% (Phase 1a, n=47 evaluable) including 2 complete responses, median PFS 22.1 months, median DOR 20.1 months, and a DCR of 95.7%. Randomized Phase 1b cohort (200 mg vs 600 mg, n=42) showed higher ORR at 600 mg: 83.3% vs 73.7% and a trend toward longer PFS; 600 mg was selected as the RP2D. Safety was consistent across doses (n=126 overall; n=70 at 600 mg) with common TEAEs including purpura/contusion, neutropenia, and petechiae; no dose-limiting toxicities, no systemic fungal infections, and no Grade 4 infections reported.
DAYBreak-CLL-201 Phase 2 is enrolling globally; a company webcast is scheduled for Dec 8, 2025, 8:15 p.m. ET.
Nurix Therapeutics (Nasdaq: NRIX) will host a live webcast on Monday, December 8, 2025 at 8:15 p.m. ET to review new and updated clinical data from the ongoing Phase 1a/1b trial of BTK degrader bexobrutideg (NX-5948) and provide a corporate update.
Presenters include investigator Alvaro Alencar, M.D., CEO Arthur T. Sands, M.D., Ph.D., and CMO Paula G. O’Connor, M.D.. The webcast and archived replay will be available in the Investors section of the Nurix website under Events and Presentations.
Nurix Therapeutics (Nasdaq: NRIX) announced that its president and CEO Arthur T. Sands, M.D., Ph.D. and CFO Hans van Houte will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 p.m. ET in New York City.
The session will be webcast live and accessible via a link in the company’s Investors section, and the archived webcast will be available for 30 days after the event.
Nurix Therapeutics (Nasdaq: NRIX) appointed Roger Dansey, M.D., to its board of directors on November 10, 2025. Dr. Dansey brings over two decades of oncology drug development and commercialization experience, including roles as Chief Development Officer and Chief Oncology Officer at Pfizer Oncology (Jan 2024–Mar 2025) and senior R&D leadership at Seagen, Merck, Gilead and Amgen.
The company said his expertise will support pivotal trials of its lead asset, bexobrutideg, in chronic lymphocytic leukemia and inform protein degradation programs for autoimmune diseases.
Nurix Therapeutics (Nasdaq: NRIX) presented translational data on Nov 7, 2025 from its ongoing Phase 1a study of oral CBL-B inhibitor NX-1607 at SITC 2025.
Key findings show dose-dependent pharmacology and target engagement (pHS1 modulation), peripheral T cell activation and proliferation correlated with stable disease versus progressive disease, and a case study in metastatic castration-resistant prostate cancer (5 prior therapies) showing stable disease with increased CD8+ TIL density and upregulated interferon and cytotoxic pathways. RNA sequencing showed dose-dependent enrichment of immune signaling pathways, linking systemic immune activation to tumor microenvironment remodeling.
Nurix Therapeutics (Nasdaq: NRIX) announced that updated clinical data from the NX-5948-301 Phase 1a/1b trial will be presented at the 67th ASH Annual Meeting, December 6–9, 2025 in Orlando.
Two company clinical presentations will feature: an oral presentation reporting new results in relapsed/refractory chronic lymphocytic leukemia (CLL) on Dec 6, 2025 at 9:45 a.m. ET, and a poster with updated Waldenström macroglobulinemia results on Dec 8, 2025 at 6:00 p.m. ET. In addition, a separate poster will present new mechanistic insights on BTK resistance (BTK A428D mutation) on Dec 6, 2025 at 5:30 p.m. ET.
The presenters named include Zulfa Omer, M.D. (CLL oral), Scott Huntington, M.D., MPH (Waldenström poster), and Quinlan Sievers, M.D., Ph.D. (BTK resistance poster).
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will participate in fireside chats at two investor conferences in November 2025:
- Stifel 2025 Healthcare Conference — New York, NY — Thursday, November 13, 2025, 9:20–9:50 a.m. ET
- Jefferies Global Healthcare Conference — London, UK — Wednesday, November 19, 2025, 11:00–11:25 a.m. GMT
The events will be webcast live and accessible via a link in the Investors section of the Nurix website. Archived webcasts will be available for 30 days after each event.
Nurix Therapeutics (Nasdaq: NRIX) closed an underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share, generating $250.0 million gross proceeds on October 27, 2025.
Nurix said it intends to use net proceeds primarily to fund clinical development of bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL), explore autoimmune indications, support R&D to expand the pipeline, and for working capital and general corporate purposes. The offering included new and existing institutional investors and was led by J.P. Morgan, Jefferies, and Stifel.
Nurix Therapeutics (Nasdaq: NRIX) priced an underwritten registered offering of 24,485,799 shares of common stock at $10.21 per share, for expected gross proceeds of $250.0 million.
The offering is expected to close on or about October 23, 2025, subject to customary closing conditions, and includes participation from new and existing investors such as General Atlantic and Redmile Group. Joint book‑running managers are J.P. Morgan, Jefferies, and Stifel.
Nurix intends to use net proceeds primarily to fund clinical development of bexobrutideg (NX‑5948) in CLL, explore autoimmune indications, expand R&D pipeline, and for working capital and general corporate purposes.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
